Announcement on the subsidiary\'s injectable cefuroxime passing the generic drug consistency evaluation
Convertible debt-to-equity conversion results and share change announcement
Announcement on the subsidiary levocarnitine injection passing the generic drug consistency evaluation
Announcement on the subsidiary\'s injectable cefazoxime sodium passing the generic drug consistency evaluation
Notice on the change of sponsor representative to continue to supervise
Announcement regarding the subsidiary's cephalosporin injection sodium sulbactam passing the generic consistency evaluation.
Announcement on Not Lowering the Conversion Price of Lingkang Convertible Bonds
Announcement regarding the expectation of meeting the share conversion price adjustment conditions for "Lingkang Convertible Bonds".
Announcement Regarding Full Subsidiary Obtaining Approval Notice for Clinical Trials of Drugs.
Announcement about the signing of a strategic cooperation framework agreement between the company and Laboratoire Bailly-Creat.
Announcement on downward revision of the conversion price of Lingkang Convertible Bonds and suspension/resumption of conversion.
Legal opinion of Zhong Lun (Shenzhen) Law Firm on Lionco Pharmaceutical Group's second extraordinary general meeting of shareholders in 2024 in Peking.
Announcement of resolution of the Second Extraordinary Shareholders' Meeting in 2024.
2024 Second Interim Shareholder Meeting Documentation
Announcement on the approval of the new specification of the subsidiary Acetylcysteine Injection.
Announcement of convertible bonds conversion results and share changes.
Announcement regarding the optional puttable results for 'Lingkang Convertible Bond'.
The Third Reminder on the Optional Redemption of Lingkang Convertible Bonds.
The Second Notice for the Optional Redemption of Lingkang Convertible Bonds.
Announcement regarding the board of directors' proposal to downwardly revise the conversion price of Lingkang Convertible Bonds.
No Data
No Data